Nykode Therapeutics AS NYKD.OL Stock
Nykode Therapeutics AS Price Chart
Nykode Therapeutics AS NYKD.OL Financial and Trading Overview
| Nykode Therapeutics AS stock price | 13.4 NOK |
| Previous Close | 29.4 NOK |
| Open | 29.4 NOK |
| Bid | 30.12 NOK x N/A |
| Ask | 30.22 NOK x N/A |
| Day's Range | 29.4 - 30.5 NOK |
| 52 Week Range | 20.18 - 39.44 NOK |
| Volume | 78.05K NOK |
| Avg. Volume | 638.45K NOK |
| Market Cap | 8.9B NOK |
| Beta (5Y Monthly) | 1.402147 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.52 NOK |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 65.5 NOK |
NYKD.OL Valuation Measures
| Enterprise Value | 8.61B NOK |
| Trailing P/E | N/A |
| Forward P/E | -24.688524 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 786.86945 |
| Price/Book (mrq) | 60.000004 |
| Enterprise Value/Revenue | 760.971 |
| Enterprise Value/EBITDA | -146.488 |
Trading Information
Nykode Therapeutics AS Stock Price History
| Beta (5Y Monthly) | 1.402147 |
| 52-Week Change | 3.30% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 39.44 NOK |
| 52 Week Low | 20.18 NOK |
| 50-Day Moving Average | 25.98 NOK |
| 200-Day Moving Average | 27.57 NOK |
NYKD.OL Share Statistics
| Avg. Volume (3 month) | 638.45K NOK |
| Avg. Daily Volume (10-Days) | 620.89K NOK |
| Shares Outstanding | 295.49M |
| Float | 60.14M |
| Short Ratio | N/A |
| % Held by Insiders | 60.19% |
| % Held by Institutions | 9.69% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -523.52% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -16.11% |
| Return on Equity (ttm) | -27.42% |
Income Statement
| Revenue (ttm) | 11.31M NOK |
| Revenue Per Share (ttm) | 0.04 NOK |
| Quarterly Revenue Growth (yoy) | 222.59% |
| Gross Profit (ttm) | 9.03M NOK |
| EBITDA | -58758000 NOK |
| Net Income Avi to Common (ttm) | -46206000 NOK |
| Diluted EPS (ttm) | -1.92 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 186.16M NOK |
| Total Cash Per Share (mrq) | 0.63 NOK |
| Total Debt (mrq) | 5.5M NOK |
| Total Debt/Equity (mrq) | 3.71 NOK |
| Current Ratio (mrq) | 5.889 |
| Book Value Per Share (mrq) | 0.502 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -51620000 NOK |
| Levered Free Cash Flow (ttm) | -34169752 NOK |
Profile of Nykode Therapeutics AS
| Country | Norway |
| State | N/A |
| City | Oslo |
| Address | Oslo Research Park |
| ZIP | 0349 |
| Phone | 47 22 95 81 93 |
| Website | https://nykode.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 158 |
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10. COV2, a COVID-19 vaccine candidate covers new SARS-CoV-2 variants. The company has collaboration agreements with Roche, Genentech, MSD, and Nektar Therapeutics; Adaptive Biotechnologies for COVID-19 T cell vaccine development; and research agreement with Regeneron. The company was formerly known as Vaccibody AS. Nykode Therapeutics AS was founded in 2006 and is based in Oslo, Norway.
Q&A For Nykode Therapeutics AS Stock
What is a current NYKD.OL stock price?
Nykode Therapeutics AS NYKD.OL stock price today per share is 13.4 NOK.
How to purchase Nykode Therapeutics AS stock?
You can buy NYKD.OL shares on the Oslo exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Nykode Therapeutics AS?
The stock symbol or ticker of Nykode Therapeutics AS is NYKD.OL.
Which industry does the Nykode Therapeutics AS company belong to?
The Nykode Therapeutics AS industry is Biotechnology.
How many shares does Nykode Therapeutics AS have in circulation?
The max supply of Nykode Therapeutics AS shares is 326.55M.
What is Nykode Therapeutics AS Price to Earnings Ratio (PE Ratio)?
Nykode Therapeutics AS PE Ratio is now.
What was Nykode Therapeutics AS earnings per share over the trailing 12 months (TTM)?
Nykode Therapeutics AS EPS is -1.52 NOK over the trailing 12 months.
Which sector does the Nykode Therapeutics AS company belong to?
The Nykode Therapeutics AS sector is Healthcare.
Nykode Therapeutics AS NYKD.OL included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| Oslo Bors All-Share Index_GI OSEAX | 1017.37 NOK 97.59 USD |
+1.04
|
371.46M NOK 35.63M USD | 1003.3 NOK 96.24 USD | 1018.4 NOK 97.69 USD | — - | 371.46M NOK 35.63M USD |
- {{ link.label }} {{link}}